Press Releases

Investor Relations

Filter by Year

November 13, 2019

Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

NEWTON, MA – Nov. 13, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2019 and provided an update on the Company’s recent […]

Read More
October 28, 2019

Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

Results Expected in Q1 2020 with a Planned NDA Submission in Q1 2021

NEWTON, MA – October 28, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of Part A in a pivotal trial evaluating bioavailability and bioequivalence of ACER-001 for the treatment […]

Read More
August 27, 2019

Acer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

NEWTON, MA – August 27, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the 21st Annual H.C. Wainwright Global Investment Conference […]

Read More
August 13, 2019

Acer Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

NEWTON, MA – August 13, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2019 and provided an update on the Company’s recent […]

Read More
August 1, 2019

Acer Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

NEWTON, MA – August 1, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference being held […]

Read More
July 25, 2019

Acer Therapeutics to Host Conference Call and Webcast to Discuss Update on its Pipeline Programs

Call to take place on Wednesday, July 31 at 11:00 am Eastern Time

NEWTON, MA – July 25, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it will host a conference call and webcast on Wednesday, July 31, 2019 at 11:00 am Eastern Time […]

Read More
July 5, 2019

Acer Therapeutics Announces Restructuring and Update on Pipeline Programs

Restructuring expected to extend cash runway through end of 2020

Acer plans to discuss EDSIVO™ CRL with FDA and will continue to advance additional pipeline products

NEWTON, MA – July 5, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced a corporate restructuring and update on its pipeline programs. Acer’s headcount has been reduced from 48 to 19 […]

Read More
June 25, 2019

Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients

NEWTON, MA – June 25, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its […]

Read More
May 31, 2019

Acer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting

Pilot study using claims database suggests that a minority of U.S. vEDS patients (34%) are being treated with antihypertensive medications

Data show no significant difference in clinical event rates in vEDS patients taking antihypertensive medications compared to those not taking an antihypertensive medication

NEWTON, MA – May 31, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the presentation and publication of results from its Pilot Study to Evaluate Effect of Antihypertensive Therapy on the […]

Read More
May 23, 2019

Acer Therapeutics to Present at Upcoming Investor Conferences

NEWTON, MA – May 23, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at upcoming investor conferences in June, including: the William […]

Read More
May 14, 2019

Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Acer executing on pre-commercial launch plan for EDSIVO™ while growing and advancing its pipeline

NEWTON, MA – May 14, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2019 and provided an update on the Company’s recent […]

Read More
May 7, 2019

Acer Therapeutics to Present at UBS Global Healthcare Conference

NEWTON, MA – May 7, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the UBS Global Healthcare Conference, May 20-22, 2019 […]

Read More
April 16, 2019

Acer Announces Publication of vEDS Patient Registry Data

NEWTON, MA – April 16, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical needs, today announced the publication of long-term data from a cohort of COL3A1-positive vEDS patients in the Journal of the American […]

Read More
March 13, 2019

Acer Therapeutics to Participate in Upcoming Investor Conferences

NEWTON, MA – March 13, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that Acer’s management team will provide a corporate overview at upcoming investor conferences in March and April, including: […]

Read More
March 7, 2019

Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Acer continues to progress toward goals of commercializing EDSIVO™ and advancing pipeline

NEWTON, MA – March 7, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today reported financial results for the quarter and full year ended December 31, 2018 and provided an update on the […]

Read More
January 2, 2019

Acer Therapeutics Announces In-license of Osanetant from Sanofi

Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist

NEWTON, MA – January 2, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that it has entered into an exclusive license agreement with Sanofi to acquire worldwide rights to osanetant, a […]

Read More
QUICK
NAV